免疫检查点抑制剂的出现彻底改变了肿瘤治疗，而与此同时，与免疫相关的不良反应（irAEs）也呈上升趋势。皮肤毒性是最常见的irAEs之一，特别是在PD-1抑制剂如Pembrolizumab的应用中。在此，我们报告了一例由抗PD-1诱导的地癞癣性天疱疮（LPP）-一种罕见的具有地癞癣和大疱性天疱疮特征的自身免疫性水疱性疾病。据我们所知，这是首次报道PD-1抑制剂治疗转移性肾上腺癌后出现LPP的案例。意识到LPP在irAEs范围内很重要，特别是随着免疫治疗的适应症扩大到包括肾上腺癌等罕见恶性肿瘤。除了我们的个案报告外，我们还提供了一份关于免疫治疗诱导LPP的文献综述-重点介绍了早期识别和临床管理这种皮肤irAE的关键特征。

While the advent of immune-checkpoint inhibitors has revolutionized cancer therapy, immune-related adverse effects (irAEs) have also been on the rise. Cutaneous toxicities are among the most common irAEs, especially in the context of programmed cell death protein-1 (PD-1) inhibitors like pembrolizumab. Herein, we report a case of anti-PD-1-induced lichen planus pemphigoides (LPP)-a rare autoimmune blistering disorder with characteristics of both lichen planus and bullous pemphigoid. To our knowledge, this is the first reported case of LPP following anti-PD-1 therapy for metastatic adrenocortical cancer. Recognizing that LPP is within the spectrum of irAEs is important, especially as the indications for immunotherapy grow to include rarer malignancies like adrenocortical cancer. In addition to our case presentation, we also provide a comprehensive review of the literature surrounding immunotherapy-induced LPP-highlighting key characteristics towards the early recognition and clinical management of this cutaneous irAE.